Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

More Good News for Neurocrine Biosciences

November 3, 2023 0

Neurocrine Biosciences’ Product INGREZZA Improved Chorea Associated with Huntington's Disease Through Week 50 Yesterday, November 2, …

ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results

November 2, 2023 0

ImmunoGen in the NEWS Immunogen (IMGN) - a developer of antibody-drug conjugates (ADCs) for cancer treatment …

Good News for CRISPR Therapeutics and Vertex Pharmaceuticals

November 1, 2023 0

CRISPR Therapeutics and Vertex Pharmaceuticals NEWS CRISPR Therapeutics (CRSP) announced the completion of the U.S. Food …

Beam Therapeutics Announces Agreement for Lilly to Acquire Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Programs for Cardiovascular Disease

October 31, 2023 0

Beam Therapeutics in the NEWS Beam Therapeutics (BEAM) announced that Eli Lilly (LLY) has agreed to …

Anavex Life Sciences Reports Publication in Scientific Journal Demonstrating the Potential of Anavex®3-71 in Preventing Cognitive Decline in Alzheimer’s Disease

October 26, 2023 0

Anavex Life Sciences NEWS Anavex Life Sciences (AVXL) reported a new peer reviewed publication in journal Neurobiology of Aging, titled “Early treatment with …

Today at 2 PM, Akero Therapeutics Presented at the H.C. Wainwright 7th Annual NASH Virtual Investor Conference

October 24, 2023 0

Akero Therapeutics Presented at the H.C. Wainwright 7th Annual NASH Conference Indeed, today, Akero Therapeutics (AKRO) …

Intellia Therapeutics: FDA Clearance of its Systemically Administered NDA of NTLA-2001 in Global Phase 3 Trial

October 18, 2023 0

Intellia Therapeutics' NTLA-2001 Intellia Therapeutics' NTLA-2001 is the first-ever investigational in vivo CRISPR-based gene editing therapy …

Intellia Therapeutics Receives PRIME Designation from the EMA for NTLA-2002 – Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema

October 14, 2023 0

Intellia Therapeutics Receives PRIME Designation from EMA Intellia Therapeutics (NTLA) announced that the European Medicines Agency …

INOVIO Receives FDA Feedback that Data from Completed Phase 1/2 Trial of INO-3107 Can be Used to Submit a BLA

October 11, 2023 0

Inovio Receives FDA Feedback for INO-3107 INOVIO (INO) - a biotechnology company focused on developing and …

Akero Therapeutics’ October 10, 2023 Press Release

October 10, 2023 0

Akero Therapeutics Press Release Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, …

Please Don’t Miss Akero Therapeutics Investor Conference Tomorrow, October 10th at 8 AM

October 9, 2023 0

Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated …

Apellis Pharmaceuticals Announces Preliminary U.S. Net Revenues of Approximately $74 M for SYFOVRE® in the Q3 2023

October 6, 2023 0

Apellis Pharmaceuticals Launch Update of SYFOVRE® On October 5, 2023, Apellis Pharmaceuticals (APLS) provided an update …

Neurocrine Biosciences Announced Positive Results from Phase 3 CAHtalyst™ Study

October 5, 2023 0

Neurocrine Biosciences Announcement Today, Neurocrine Biosciences (NBIX) announced positive top-line data from the Phase 3 CAHtalyst™ …

Akero Therapeutics Announced Publication in the Lancet Gastroenterology & Hepatology of HARMONY Phase 2b Trial Results for NASH

October 4, 2023 0

Akero Therapeutics Akero Therapeutics (AKRO) announced publication in The Lancet Gastroenterology & Hepatology of results from …

Soleno Therapeutics Announces Positive Top-Line Results of Its Product DCCR for the Treatment of Prader-Willi Syndrome

September 28, 2023 0

Soleno Therapeutics Soleno Therapeutics (SLNO) is focused on the development and commercialization of novel therapeutics for …

Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast

September 26, 2023 0

Pliant Therapeutics in the NEWS Treating Primary Sclerosing Cholangitis Pliant Therapeutics (PLRX) today announced positive data …

Reata Stock Holders Approved the Firm’s Merger with Biogen

September 21, 2023 0

Reat Pharmaceuticals Merger with Biogen Reata Pharmaceuticals announced that at a special meeting held today, preliminary …

Publication of Two Cases for Treatment of Metastatic Pancreatic Cancer by CARsgen Therapeutics Holdings Limited

September 21, 2023 0

CARsgen Therapeutics Holdings Limited Today, September 21, 2023, CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK) - …

Orchard Therapeutics: FDA Acceptance of BLA Application for Product OTL-200 for the Treatment of Metachromatic Leukodystrophy

September 18, 2023 0

Orchard Therapeutics in the NEWS Today, September 18, 2023, Orchard Therapeutics (ORTX) - a global gene …

Discovering The Root Causes of Diseases

September 15, 2023 0

Prohost Letter #457 Discovering The Root Causes of Diseases Biotech firms with solid scientific fundamentals …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

More Good News for Neurocrine Biosciences

ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results

Good News for CRISPR Therapeutics and Vertex Pharmaceuticals

Beam Therapeutics Announces Agreement for Lilly to Acquire Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Programs for Cardiovascular Disease

Anavex Life Sciences Reports Publication in Scientific Journal Demonstrating the Potential of Anavex®3-71 in Preventing Cognitive Decline in Alzheimer’s Disease

Today at 2 PM, Akero Therapeutics Presented at the H.C. Wainwright 7th Annual NASH Virtual Investor Conference

Intellia Therapeutics: FDA Clearance of its Systemically Administered NDA of NTLA-2001 in Global Phase 3 Trial

Intellia Therapeutics Receives PRIME Designation from the EMA for NTLA-2002 – Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema

INOVIO Receives FDA Feedback that Data from Completed Phase 1/2 Trial of INO-3107 Can be Used to Submit a BLA

Akero Therapeutics’ October 10, 2023 Press Release

Please Don’t Miss Akero Therapeutics Investor Conference Tomorrow, October 10th at 8 AM

Apellis Pharmaceuticals Announces Preliminary U.S. Net Revenues of Approximately $74 M for SYFOVRE® in the Q3 2023

Neurocrine Biosciences Announced Positive Results from Phase 3 CAHtalyst™ Study

Akero Therapeutics Announced Publication in the Lancet Gastroenterology & Hepatology of HARMONY Phase 2b Trial Results for NASH

Soleno Therapeutics Announces Positive Top-Line Results of Its Product DCCR for the Treatment of Prader-Willi Syndrome

Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast

Reata Stock Holders Approved the Firm’s Merger with Biogen

Publication of Two Cases for Treatment of Metastatic Pancreatic Cancer by CARsgen Therapeutics Holdings Limited

Orchard Therapeutics: FDA Acceptance of BLA Application for Product OTL-200 for the Treatment of Metachromatic Leukodystrophy

Discovering The Root Causes of Diseases